Insider · CIK 0001748894
Marc Grasso
Files at ALEC (Alector, Inc.), KYTX (Kyverna Therapeutics, Inc.). First filing Dec 6, 2023, latest Jun 4, 2025.
In brief
Marc Grasso files SEC Form 4 as CFO at ALEC (Alector, Inc.), and also at KYTX (Kyverna Therapeutics, Inc.). Since Dec 6, 2023, Marc Grasso has reported 0 open-market buys worth $0 and 4 open-market sells worth $116k, the latest filed on Jun 4, 2025.
A track record needs three past buys with six months of prices behind them; Marc Grasso has 0, so none is measured yet.
The newest scored trade: sold $22k of ALEC on Jun 2, 2025, filed Jun 4, 2025, scored 37 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALEC: Alector, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Alector, Inc. | $22k 16,488 shares | -5% | +53% from low-78% from high | |
| 42Moderate | Alector, Inc. | $27k 18,091 shares | -5% | 0% from low-77% from high | |
| 43Moderate | Alector, Inc. | $42k 16,489 shares | -5% | - | |
| 42Moderate | Alector, Inc. | $25k 4,574 shares | -3% | +49% from low-43% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 8, 2025 | ALEC ALECTOR, INC. | 76,446 0.08% of outstanding | $153k | Aug 8, 2025 | $22k |
| May 30, 2025 | ALEC Alector, Inc. | 15,873 0.02% of outstanding | $21k | Jun 2, 2025 | $27k |
| Feb 28, 2025 | ALEC Alector, Inc. | 15,873 0.02% of outstanding | $26k | Mar 3, 2025 | $42k |
| Nov 29, 2024 | ALEC Alector, Inc. | 15,842 0.02% of outstanding | $41k | Dec 2, 2024 | $36k |
| Mar 1, 2024 | ALEC Alector, Inc. | 5,315 0.01% of outstanding | $39k | Mar 4, 2024 | $25k |
| Dec 1, 2023 | ALEC Alector, Inc. | 4,574 0.01% of outstanding | $25k | Dec 4, 2023 | $5,786 |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Mar 17, 2026 |
| Mar 13, 2026 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Mar 17, 2026 |
| Jun 30, 2025 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | -450,000 | $0.00 | $0 | 450,000 | Jul 1, 2025 |
| Jun 2, 2025 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -16,488 | $1.34 | $22k | 296,072 | Jun 4, 2025 |
| Mar 3, 2025 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -18,091 | $1.47 | $27k | 312,560 | Mar 5, 2025 |
| Dec 2, 2024 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -16,489 | $2.52 | $42k | 330,651 | Dec 3, 2024 |
| Dec 4, 2023 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -4,574 | $5.56 | $25k | 150,673 | Dec 6, 2023 |
Questions about Marc Grasso
Answered from the filings on this page, as of the latest one.
Is Marc Grasso buying or selling?
Not in the last 12 months. Marc Grasso's latest open-market trade on SEC Form 4 was sold $22k of ALEC on Jun 2, 2025.
How did Marc Grasso's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Marc Grasso has 0.
Where does Marc Grasso file Form 4?
Marc Grasso has filed Form 4 at ALEC (Alector, Inc.) as Chief Financial Officer; KYTX (Kyverna Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.